Get the Stockscreener App
0.6927
1.66%
0.0113
After Hours:
.70
0.0073
+1.05%
Pds Biotechnology Corp stock is traded at $0.6927, with a volume of 363.08K.
It is up +1.66% in the last 24 hours and down -22.04% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
See More
Previous Close:
$0.6814
Open:
$0.6875
24h Volume:
363.08K
Relative Volume:
0.48
Market Cap:
$38.74M
Revenue:
-
Net Income/Loss:
$-33.36M
P/E Ratio:
-1.033
EPS:
-0.6706
Net Cash Flow:
$-23.09M
1W Performance:
-3.43%
1M Performance:
-22.04%
6M Performance:
-22.96%
1Y Performance:
-41.30%
1-Day Range:
$0.65
$0.715
1-Week Range:
$0.65
$0.777
52-Week Range:
$0.5068
$1.55
Pds Biotechnology Corp Stock (PDSB) Company Profile
Name
Pds Biotechnology Corp
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
0.6927 | 38.11M | 0 | -33.36M | -23.09M | -0.6706 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corp Stock (PDSB) Latest News
PDS Biotechnology Corp (PDSB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PDS Biotechnology Corp (PDSB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PDS Biotechnology Corp (PDSB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
PDS Biotechnology Corp (PDSB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PDSB|PDS Biotechnology Corp|Price:0.720|Chg%:+0.039 - TradingKey
PDSB|PDS Biotechnology Corp|Price:0.681|Chg%:-0.019 - TradingKey
PDS Biotechnology Corp. Revenue Breakdown – FWB:EU6 - TradingView
PDS Biotechnology Corp (PDSB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PDS Biotechnology Corp SEC Filing (Jul 22, 2026) - Stock Titan
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Form S-3 PDS Biotechnology Corp For: 10 July By Investing.com - Investing.com South Africa
PDS Biotechnology (NASDAQ: PDSB) registers 13.3M shares tied to note and warrant deal - Stock Titan
PDSB | PDS Biotechnology Corporation Common Executive Compensation - Quiver Quantitative
PDS Biotechnology (PDSB) Hovers Near Support Amid Modest DeclineVolume Breadth - dars.gov.et
PDS Biotechnology Corp (PDSB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PDS Biotechnology (NASDAQ: PDSB) details 2026 proxy votes and pay - Stock Titan
PDS Biotechnology Corp. Actuals & Estimates (NASDAQ:PDSB) - TradingView
PDS Biotechnology Corp. Actuals & Estimates (DUS:EU6) - TradingView
PDSB Forecast — Price Target — Prediction for 2027 - TradingView
PDS Biotech’s Double Squeeze: Nasdaq Clock Ticking as Equity Dilution Looms - AD HOC NEWS
PDS Biotechnology Corp (PDSB) Institutional Confidence - TradingKey
PDS Biotechnology Corp (PDSB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PDS Biotechnology Corp (PDSB) Valuation: PE, PB & Fair Value Analysis - TradingKey
PDS Biotechnology Closes Financing and Retires Convertible Debentures - TipRanks
PDS Biotechnology (NASDAQ: PDSB) launches $50M ATM program tied to YA II financing - Stock Titan
[PRE 14A] PDS Biotechnology Corp Preliminary Proxy Statement - Stock Titan
PDS Biotechnology (NASDAQ: PDSB) adds $6M note and $50M at-the-market stock program - Stock Titan
PDS Biotechnology schedules 2026 annual meeting for Aug. 10; stockholder proposal deadline set - TradingView
PDS Biotechnology (PDSB) schedules 2026 annual meeting and sets June 25 proposal cutoff - Stock Titan
PDS Biotechnology establishes up to $50M stock offering program - scanx.trade
PDSB Q1 2026 Earnings: EPS Beat Fails to Lift Shares as Pipeline Progress AwaitedROA Comparison - dars.gov.et
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher - MSN
PDS Biotechnology Corporation - MLQ.ai
PDS Biotechnology Stock Gets Nasdaq Extension as Traders Eye PDSB - Bez Kabli
PDS Biotechnology (NASDAQ: PDSB) back in compliance with Nasdaq $1.00 bid rule - Stock Titan
PDSB Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Pipeline ProgressGuidance Upgrade Report - dars.gov.et
PDS Biotechnology (PDSB) Slides 3.6% as Stock Tests Key Support Near $1.02Breakaway Gap - The Legal Advocate
PDSB Q1 2026 Earnings: Narrower Loss Drives Positive EPS Surprise Amid Pre-Revenue PhaseHealthcare Earnings Report - dars.gov.et
PDSBPDS Biotechnology Corp Stock Price and Quote - Finviz
PDSB Q4 2025 Earnings Call Transcript - Yahoo Finance
PDS Biotechnology Q1 2026 Earnings: EPS Beat on Narrower Loss, Clinical Progress in FocusReturn On Capital - Newser
PDS Biotechnology (PDSB) Edges Higher by 1.82% as Biotech Speculative Interest PersistsIron Condor Alert - dars.gov.et
PDS Biotechnology Q1 2026 Earnings: Narrowed Loss Per Share and Clinical Progress Drive Positive Market ResponseGrowth Acceleration Report - thelegaladvocate.com
PDS Biotechnology Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock Up 3.45%Earnings Growth Forecast - Newser
PDS Biotechnology Q1 2026 Earnings: EPS Beat Highlights Progress Despite Pre-Revenue StatusEarnings Forecast Report - newsline.com
PDS (PDSB) Q1 2026 Beat: Revenue $N/A, EPS Exceeds by SignificantPositive Surprise Momentum - The Legal Advocate
ETFs Investing in PDS Biotechnology Corp. Stocks - TradingView
PDS Biotechnology Q1 2026 earnings preview - MSN
Number of shareholders of PDS Biotechnology Corp. – SWB:EU6 - TradingView
PDS Biotechnology: Juni-Test für Wandelanleihe - kapitalmarktexperten.de
Pds Biotechnology Corp Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):